高级检索
当前位置: 首页 > 详情页

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, People’s Republic of China [2]Department of Immuno‑Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, People’s Republic of China [3]Department of Ultrasound, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, People’s Republic of China
出处:

关键词: pH-activatable Tumor immunotherapy cGAS-STING pathway Ferroptosis Photodynamic therapy

摘要:
Immunotherapy exhibits considerable promise for sustained tumor reduction. However, current cancer immunotherapy methods elicit limited responses due to the inadequate immunogenicity exhibited by cancer cells. This obstacle may be addressed using nanoplatforms that can activate synergistic therapies (photodynamic therapy and ferroptosis) in response to the acidic pH of the tumor microenvironment. We previously developed an amphiphilic photosensitizer, SR780, which displays satisfactory photodynamic effects. This photosensitizer is inactivated when bound to Fe3+ (SR780Fe) but is activated upon release in mildly acidic conditions. In this study, M1 macrophage-derived extracellular vesicles (EVs) were fused with REV and SR780Fe-loaded liposomes (REV@SR780Fe@Lip) to form REV@SR780Fe@LEV hybrid nanovesicles. Further modification with the RS17 peptide for tumor targeting enabled a combination of photodynamic therapy, ferroptosis, and cGAS-STING pathway activation, resulting in enhanced antitumor efficacy through a synergistic effect. Upon laser irradiation, REV@SR780Fe@LEV-RS17 demonstrated antitumor effects in 4T1 breast cancer models, including the inhibition of lung and liver metastasis, as well as prevention of tumor recurrence.© 2024. The Author(s).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 1 区 生物学
小类 | 1 区 生物工程与应用微生物 2 区 纳米科技
最新[2025]版:
大类 | 1 区 生物学
小类 | 1 区 生物工程与应用微生物 2 区 纳米科技
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 NANOSCIENCE & NANOTECHNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, People’s Republic of China [2]Department of Immuno‑Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, People’s Republic of China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号